Deciphering breast cancer: from biology to the clinic
E Nolan, GJ Lindeman, JE Visvader - Cell, 2023 - cell.com
Breast cancer remains a leading cause of cancer-related mortality in women, reflecting
profound disease heterogeneity, metastasis, and therapeutic resistance. Over the last …
profound disease heterogeneity, metastasis, and therapeutic resistance. Over the last …
Pathogenesis of triple-negative breast cancer
F Derakhshan, JS Reis-Filho - Annual Review of Pathology …, 2022 - annualreviews.org
Triple-negative breast cancer (TNBC) encompasses a heterogeneous group of
fundamentally different diseases with different histologic, genomic, and immunologic …
fundamentally different diseases with different histologic, genomic, and immunologic …
Multi-omic machine learning predictor of breast cancer therapy response
Breast cancers are complex ecosystems of malignant cells and the tumour
microenvironment. The composition of these tumour ecosystems and interactions within …
microenvironment. The composition of these tumour ecosystems and interactions within …
Substitution mutational signatures in whole-genome–sequenced cancers in the UK population
A Degasperi, X Zou, T Dias Amarante… - Science, 2022 - science.org
Whole-genome sequencing (WGS) permits comprehensive cancer genome analyses,
revealing mutational signatures, imprints of DNA damage, and repair processes that have …
revealing mutational signatures, imprints of DNA damage, and repair processes that have …
DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy
R Huang, PK Zhou - Signal transduction and targeted therapy, 2021 - nature.com
Genomic instability is the hallmark of various cancers with the increasing accumulation of
DNA damage. The application of radiotherapy and chemotherapy in cancer treatment is …
DNA damage. The application of radiotherapy and chemotherapy in cancer treatment is …
Patient-derived xenograft (PDX) models, applications and challenges in cancer research
S Abdolahi, Z Ghazvinian, S Muhammadnejad… - Journal of Translational …, 2022 - Springer
The establishing of the first cancer models created a new perspective on the identification
and evaluation of new anti-cancer therapies in preclinical studies. Patient-derived xenograft …
and evaluation of new anti-cancer therapies in preclinical studies. Patient-derived xenograft …
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Developing novel targeted anticancer therapies is a major goal of current research. The use
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …
The rediscovery of platinum-based cancer therapy
S Rottenberg, C Disler, P Perego - Nature Reviews Cancer, 2021 - nature.com
Platinum (Pt) compounds entered the clinic as anticancer agents when cisplatin was
approved in 1978. More than 40 years later, even in the era of precision medicine and …
approved in 1978. More than 40 years later, even in the era of precision medicine and …
Inherited causes of clonal haematopoiesis in 97,691 whole genomes
Age is the dominant risk factor for most chronic human diseases, but the mechanisms
through which ageing confers this risk are largely unknown. The age-related acquisition of …
through which ageing confers this risk are largely unknown. The age-related acquisition of …
Mutational signatures: emerging concepts, caveats and clinical applications
Whole-genome sequencing has brought the cancer genomics community into new territory.
Thanks to the sheer power provided by the thousands of mutations present in each patient's …
Thanks to the sheer power provided by the thousands of mutations present in each patient's …